Cardiomyopathies

A subpopulation of cardiac-resident macrophages protect the heart against sepsis-induced cardiomyopathy by scavenging dysfunctional mitochondria ejected from cardiomyocytes; modulation or administration of these macrophages might be a potential therapeutic strategy.

A landscape view of metabolic remodeling in end-stage human failing hearts generated by multiomics analysis confirms main changes in cardiac energy metabolism and challenges several widely held mechanisms derived from animal models. Further validation in non-end-stage heart failure and metabolic flux analysis will be necessary to move the field forward.

Overexpression of a circular RNA derived from the gene encoding the insulin receptor (Circ-INSR) prevents the development of cardiac dysfunction that occurs in response to anti-cancer therapy with doxorubicin.

The US FDA recently approved mavacamten, a first-in-class myosin modulator, for obstructive hypertrophic cardiomyopathy. By targeting actin mechanobiology, myosin modulators are emerging as important medicines in cardiology.

Activating the serine biosynthesis pathway might be a potential strategy for the treatment of dilated cardiomyopathy, according to a phenotypic screening study.